Last reviewed · How we verify
brimonidine tartrate ophthalmic solution
Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | brimonidine tartrate ophthalmic solution |
|---|---|
| Also known as | Alphagan®, Concomitant triple therapy |
| Sponsor | Allergan |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor (the fluid inside the eye) and enhances its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The drug has minimal systemic absorption when applied topically to the eye.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia (eye redness)
- Ocular allergic reactions
- Dry mouth
- Fatigue
- Headache
- Blurred vision
- Tachyphylaxis (reduced efficacy over time)
Key clinical trials
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE2)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Upneeq vs. Lumify Ptosis (PHASE4)
- Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (PHASE4)
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- brimonidine tartrate ophthalmic solution CI brief — competitive landscape report
- brimonidine tartrate ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI